Navigation Links
Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
Date:5/19/2008

er-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.

Amarin Corporation plc

Period Ended 31 December 2007 (IFRS - UNAUDITED)

Selected Income Statement Data

Three months Twelve months

ended ended

31 31

December December

2007 2006 2007 2006

Total Total Total Total

$'000 $'000 $'000 $'000

Revenue - 400 - 500

Gross profit - 400 - 500

Operating expenses:

Research and development 1,748 3,925 10,772 14,380

Selling, General &

Administrative 3,222 2,516 14,109 11,311

Amortization of intangible

assets - 170 169 676

Impairment of intangible

fixed assets (non-cash) - - 8,784 -

Reorganization costs 1,898 1,898 -

Share-based compensa
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amarin Secures Global Intellectual Property Rights for Lipid Programs
2. Amarin Appoints Dr. William Mason as Lead Independent Director
3. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
4. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
7. Amarin Announces Initiation of Cardiovascular Development Strategy
8. Amarin to Present at 4th Annual Bio Investor Forum
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Volcano Announces Acquisition of Novelis, Inc.
11. RainDance Announces Company Relocation and Manufacturing Startup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... --  Synageva BioPharma Corp. (NASDAQ: GEVA ... disorders, announced today its presentation at the upcoming J.P. ... Francisco, CA. Sanj K. ... on Monday, January 12, 2015, at 9:00 a.m. PST ... and may be accessed from the "Webcasts & Presentations" ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... understanding in the field of, bioabsorbable ... 2008, ORANGEBURG, S.C., Aug. 22 Zeus, ... announce it will be hosting an informative,and cutting-edge ... Dr. Bruce Anneaux and James Lindsey, the,webinar will ...
... The inability of the Consumer Product Safety Commission (CPSC) ... products such as children,s jewelry and toy trains bodes poorly ... products made using nanotechnology, according to a new report released ... nanotech products under the jurisdiction of the CPSC are being ...
... Calif., Aug. 21 Telik, Inc.,(Nasdaq: TELK ... its Aurora kinase,and VEGFR dual inhibitor program met ... signaling enzyme whose function is required for,cancer cell ... a key role in tumor blood vessel formation, ...
Cached Biology Technology:Zeus Webinar: Bioabsorbable Polymers as Biomaterials 2Consumer Product Safety Commission not ready for nanotech 2Consumer Product Safety Commission not ready for nanotech 3Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone 2
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... DURHAM, N.C. -- Going smaller could bring ... drugs. Duke University bioengineers have developed a ... payloads into nano-scale delivery vehicles and demonstrated in ... tumors after a single treatment. After delivering the ...
... /- PlatformQ , a digital media company that ... and LabRoots , a free social networking site serving ... and CEO for GE Healthcares Americas region, will speak at ... PM. GE Healthcare is interested in supporting new ...
... wife team of American paleontologists has discovered a new species of ... of central Montana. The new dinosaur, a species of ankylosaur, ... of Earth Sciences . Ankylosaurs are the biological version of an ... sets of sharp spikes on each side of the head, and ...
Cached Biology News:Duke develops nano-scale drug delivery for chemotherapy 2GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live 2New dinosaur species from Montana 2
... human omental preadipocytes are ... otherwise healthy donors. There ... diabetic cells. Please inquire ... media also available. Academic ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
...
Biology Products: